Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Investigation of Chiasma

By PR Newswire | April 18, 2016

Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Chiasma, Inc. and certain of its officers and directors. Chiasma is a late-stage biopharmaceutical company that focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases.

Specifically, Johnson & Weaver’s investigation seeks to determine whether the company’s filings with the U.S. Securities and Exchange Commission in connection with its July 2015 initial public stock offering (IPO) contained untrue statements of material facts or omitted to state other facts necessary to make the statements made therein not misleading concerning the company’s business and financial prospects.

In July 2015, Chiasma offered more than 6,300,000 shares of its common stock at $16.00 per share in connection with its IPO. Chiasma shares are plunging and were trading below $4.50 per share during pre-market trading on April 18, 2016. The stock dropped following the FDA rejection of the company’s drug to treat acromegaly, a rare disease of the pituitary gland.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE